New Delhi News

Liver Cancer Market and Epidemiology Forecast 2032: Population Data, Drugs, Companies and Competitive Intelligence by DelveInsight | Pfizer, GlaxoSmithKline, Kyowa Kirin Co., Ltd., Hoffmann-La Roche

 Breaking News
  • No posts were found

Liver Cancer Market and Epidemiology Forecast 2032: Population Data, Drugs, Companies and Competitive Intelligence by DelveInsight | Pfizer, GlaxoSmithKline, Kyowa Kirin Co., Ltd., Hoffmann-La Roche

May 11
19:34 2023
Liver Cancer Market and Epidemiology Forecast 2032: Population Data, Drugs, Companies and Competitive Intelligence by DelveInsight | Pfizer, GlaxoSmithKline, Kyowa Kirin Co., Ltd., Hoffmann-La Roche
DelveInsight’s “Liver Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Liver Cancer.

DelveInsight’s “Liver Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Liver Cancer, historical and forecasted epidemiology as well as the Liver Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Liver Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Liver Cancer Market Forecast

 

Some of the key facts of the Liver Cancer Market Report: 

  • The Liver Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • The Global Cancer Observatory estimates that in the 7MM, the ASR incident rate of liver cancer is 7.4/100,000, which translates to approximately 135,530 new cases in 2020, and the ASR fatality rate is 4.8/100,000, which translates to approximately 100,790 fatalities in 2020
  • According to the Global Cancer Observatory, the incidence rate of liver cancer in Japan is 10.4/100,000, which corresponds to an estimated 45,660 new cases being diagnosed in 2020, and the incidence rate of liver cancer mortality is 4.8/100,000, which corresponds to an estimated 28,155 deaths in 2020
  • In the United States, the incident rate of liver cancer and intrahepatic bile duct cancer was 9.0 per 100,000, translating to an expected 42,230 new cases in 2021, according to Surveillance, Epidemiology, and End Results (SEER)
  • Key Liver Cancer Companies: Pfizer, GlaxoSmithKline, Kyowa Kirin Co., Ltd., Hoffmann-La Roche, Eli Lilly and Company, Guerbet, CStone Pharmaceuticals, SOTIO Biotech, Akeso Biopharma, Adagene Inc., Tempest Therapeutics, Eximias Pharmaceutical, Daiichi Sankyo, Inc., Bristol-Myers Squibb, Jiangsu HengRui Medicine Co., Ltd., and others
  • Key Liver Cancer Therapies: Sunitinib (SU011248), TSR-022 and TSR-042, ARQ197, bevacizumab [Avastin], Pemetrexed, Lipiodol, Nofazinlimab, Nanrilkefusp alfa (formerly SOT101), AK112, Bevacizumab, Tiragolumab, doxorubicin hydrochloride, exatecan mesylate, Brivanib, Apatinib, PD-0332991, and others
  • The Liver Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Liver Cancer pipeline products will significantly revolutionize the Liver Cancer market dynamics.

 

Liver Cancer Overview

One type of cancer that begins in the liver is known as liver cancer. It is the third most common cause of cancer death and the sixth most frequent malignancy to be diagnosed globally. Primary liver cancer primarily manifests as hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA).

 

Get a Free sample for the Liver Cancer Market Report –

https://www.delveinsight.com/sample-request/liver-cancer-market

 

Liver Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Liver Cancer Epidemiology Segmentation:

The Liver Cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Liver Cancer
  • Prevalent Cases of Liver Cancer by severity
  • Gender-specific Prevalence of Liver Cancer
  • Diagnosed Cases of Episodic and Chronic Liver Cancer

 

Download the report to understand which factors are driving Liver Cancer epidemiology trends @ Liver Cancer Epidemiology Forecast

 

Liver Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Liver Cancer market or expected to get launched during the study period. The analysis covers Liver Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Liver Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Liver Cancer Therapies and Key Companies

  • Sunitinib (SU011248): Pfizer
  • TSR-022 and TSR-042: GlaxoSmithKline
  • ARQ197: Kyowa Kirin Co., Ltd.
  • bevacizumab [Avastin]: Hoffmann-La Roche
  • Pemetrexed: Eli Lilly and Company
  • Lipiodol: Guerbet
  • Nofazinlimab: CStone Pharmaceuticals
  • Nanrilkefusp alfa (formerly SOT101): SOTIO Biotech
  • AK112: Akeso Biopharma
  • Bevacizumab: Adagene Inc.
  • Tiragolumab: Tempest Therapeutics
  • doxorubicin hydrochloride: Eximias Pharmaceutical
  • exatecan mesylate: Daiichi Sankyo, Inc.
  • Brivanib: Bristol-Myers Squibb
  • Apatinib: Jiangsu HengRui Medicine Co., Ltd.
  • PD-0332991: Pfizer

 

Discover more about therapies set to grab major Liver Cancer market share @ Liver Cancer Treatment Market

 

Liver Cancer Market Strengths

  • Increasing incidence due to the change in lifestyle, increasing obesity etc
  • Presence of a strong pipeline is expected to bring a positive change in the market

 

Liver Cancer Market Opportunities

  • Increase in awareness owing to the efforts being put in educating people about diseases plays an important part

 

Scope of the Liver Cancer Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Liver Cancer Companies: Pfizer, GlaxoSmithKline, Kyowa Kirin Co., Ltd., Hoffmann-La Roche, Eli Lilly and Company, Guerbet, CStone Pharmaceuticals, SOTIO Biotech, Akeso Biopharma, Adagene Inc., Tempest Therapeutics, Eximias Pharmaceutical, Daiichi Sankyo, Inc., Bristol-Myers Squibb, Jiangsu HengRui Medicine Co., Ltd., and others
  • Key Liver Cancer Therapies: Sunitinib (SU011248), TSR-022 and TSR-042, ARQ197, bevacizumab [Avastin], Pemetrexed, Lipiodol, Nofazinlimab, Nanrilkefusp alfa (formerly SOT101), AK112, Bevacizumab, Tiragolumab, doxorubicin hydrochloride, exatecan mesylate, Brivanib, Apatinib, PD-0332991, and others
  • Liver Cancer Therapeutic Assessment: Liver Cancer current marketed and Liver Cancer emerging therapies
  • Liver Cancer Market Dynamics: Liver Cancer market drivers and Liver Cancer market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Liver Cancer Unmet Needs, KOL’s views, Analyst’s views, Liver Cancer Market Access and Reimbursement 

 

To know more about Liver Cancer companies working in the treatment market, visit @ Liver Cancer Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Liver Cancer Market Report Introduction

2. Executive Summary for Liver Cancer

3. SWOT analysis of Liver Cancer

4. Liver Cancer Patient Share (%) Overview at a Glance

5. Liver Cancer Market Overview at a Glance

6. Liver Cancer Disease Background and Overview

7. Liver Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Liver Cancer 

9. Liver Cancer Current Treatment and Medical Practices

10. Liver Cancer Unmet Needs

11. Liver Cancer Emerging Therapies

12. Liver Cancer Market Outlook

13. Country-Wise Liver Cancer Market Analysis (2019–2032)

14. Liver Cancer Market Access and Reimbursement of Therapies

15. Liver Cancer Market Drivers

16. Liver Cancer Market Barriers

17.  Liver Cancer Appendix

18. Liver Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Related Articles